Nicolas Leupin

CIK: 0002007766

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (80.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (20.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

NVCR

NovoCure Ltd

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

NVCR
NovoCure Ltd
Mar 4, 2026
Sale(S)
Direct
1.1K shares at avg. $13.31$15K
NVCR
NovoCure Ltd
Feb 27, 2026
Sale(S)
Direct
1K shares at avg. $13.66$14K
NVCR
NovoCure Ltd
Mar 4, 2025
Award(A)
Direct
55K shares at avg. $18.19$1000K
NVCR
NovoCure Ltd
Feb 27, 2025
Sale(S)
Direct
830 shares at avg. $19.92$17K
NVCR
NovoCure Ltd
Feb 27, 2025
Sale(S)
Direct
161 shares at avg. $20.55$3K

		Type	Shares	Price		Ownership
Mar 4, 2026	NVCR NovoCure Ltd	Sale(S)	1,100	$13.31	$14,636	Direct
Feb 27, 2026	NVCR NovoCure Ltd	Sale(S)	1,029	$13.66	$14,060	Direct
Mar 4, 2025	NVCR NovoCure Ltd	Award(A)	54,975	$18.19	$999,995	Direct
Feb 27, 2025	NVCR NovoCure Ltd	Sale(S)	830	$19.92	$16,535	Direct
Feb 27, 2025	NVCR NovoCure Ltd	Sale(S)	161	$20.55	$3,308	Direct

1-5 of 5 transactions

About Leupin Nicolas

Leupin Nicolas (SEC CIK 0002007766) files insider reports with the SEC as Former Chief Medical Officer of NovoCure Ltd (NVCR).

Signal8 holds 5 ownership filings by Leupin Nicolas, all Form 4s, filed between Mar 3, 2025 and Mar 5, 2026. Those filings report 5 transactions, from Feb 27, 2025 to Mar 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Leupin Nicolas's filings is in WAYNE, PA.

Recent filings by Leupin Nicolas

Mar 4, 2026: Open-market sale of NVCR shares (Form 4, code S).
Feb 27, 2026: Open-market sale of NVCR shares (Form 4, code S).
Mar 4, 2025: Grant or award of NVCR shares (Form 4, code A).
Feb 27, 2025: Open-market sales of NVCR shares (2 lines, Form 4, code S).

Other insiders filing for NovoCure Ltd (NVCR)

Puri Michal Nath, Chief Human Resources Officer
Leonard Frank X, Chief Executive Officer
Ben Arye Barak, General Counsel
Danziger Asaf, Director
LEUNG GABRIEL, Director
Stafford Kristin, Director

How to read Form 4 transaction codes